Borderline Personality Disorder (BPD)IFS for BPDNCT07342907
Internal Family Systems Therapy for Borderline Personality Disorder
A study testing Internal family systems therapy in people with Borderline Personality Disorder (BPD), run by Waypoint Centre for Mental Health Care at 1 site in Canada.
Trial summary
Borderline Personality Disorder (BPD) involves intense emotional ups and downs, unstable relationships, impulsivity, and a poor sense of self. These challenges often lead to addiction, self-harm, and frequent use of healthcare services. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Borderline Personality Disorder (BPD)
- What is being tested?
- Internal family systems therapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteCanada
- Study dates
- Feb 2026to Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Resident of Ontario, Canada;
- Sufficient fluency in English to provide informed consent, participate in therapy sessions, and complete self-reported assessments;
- Diagnosis of borderline personality disorder confirmed by a healthcare professional authorized to establish such a diagnosis in Ontario;
- Willingness and ability (including financial means) to participate in the 50-session, 12-15-month intervention and the study assessments;
- Capacity and willingness to provide written informed consent.
Who cannot join
- Current manic or psychotic symptoms regardless of diagnosis;
- Substance dependence severe enough to interfere with meaningful level of engagement in the study intervention.
- Cognitive impairment or neurological disorders that would preclude informed consent or meaningful participation in the study intervention.
- Concurrent participation in any another form of psychotherapy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
Provincewide across Ontario (intervention can be delivered virtually)
Tiny, Ontario
Barna Konkoly-Thege, PhD, 705-549-3181 ext. 2614, bkonkoly-thege@waypointcentre.ca
Stephanie Munten-Chisholm, MSc, smunten@waypointcentre.ca
About this study
Official title: Effectiveness of Internal Family Systems Therapy in Improving Mental Health in Individuals With Borderline Personality Disorder
Borderline Personality Disorder (BPD) involves intense emotional ups and downs, unstable relationships, impulsivity, and a poor sense of self. These challenges often lead to addiction, self-harm, and frequent use of healthcare services. While certain treatments already in practice - such as dialectical behavior therapy - can help, they don't work for everyone or address all aspects of the disorder. This study plans to explore internal family systems (IFS) therapy, a method that views the mind as made up of different "parts" - each with its own thoughts and feelings. IFS helps people build understanding and compassion toward these parts and connect with a calmer, more centered "Self." This may be especially useful for those with BPD, who often feel fragmented and extremely critical of themselves and others. This will be the first study to examine internal family systems therapy for BPD. The participants (15 in total) will receive up to 50 individual sessions over 15 months. Changes in symptoms and overall mental health will be measured at four points during the study. People with lived experience of BPD will help shape the research to ensure it is relevant, respectful, and useful for others facing similar challenges.
Read the detailed description
Brief background and rationale: Borderline personality disorder (BPD) is a chronic and disabling psychiatric condition marked by pervasive affective instability, identity disturbance, interpersonal dysfunction, and impulsivity. It affects approximately 1-2% of the general population and up to 20% of psychiatric populations, contributing substantially to healthcare utilization, suicide risk, and long-term disability. Existing evidence-based psychotherapies for this condition, such as dialectical behavior therapy, mentalization-based therapy, or schema therapy show significant benefits but these are modest and these interventions are quite resource-intensive. There remains a need for additional, theoretically grounded treatments that target core pathomechanisms of BPD-particularly emotion dysregulation, shame, and self-fragmentation.
Objectives: The primary objective of this pilot study is to assess preliminary effectiveness of internal family systems (IFS) therapy in reducing BPD symptom severity from baseline to post-treatment. Secondary objectives are to evaluate changes in emotion dysregulation, shame, self-compassion, interpersonal functioning, depression, anxiety, addictive behaviors and overall well-being; as well as to assess feasibility (recruitment, retention, adherence), acceptability, and safety. It is hypothesized that participants will demonstrate at least small-to-moderate improvements in BPD symptom severity, with congruent changes across secondary outcomes. Although clinical interest in IFS has grown exponentially in the past decades, empirical evaluation remains limited, and no studies to date have specifically examined its use in any personality disorder. Given the strong theoretical fit between IFS principles and BPD phenomenology, a structured pilot investigation is warranted to establish feasibility, safety, and preliminary effectiveness prior to larger controlled trials.
Study design: The study will use a single-group, repeated-measures design with assessments at baseline, 4 months, 8 months, and post-intervention (12-15 months). A target sample of fifteen adults will be recruited. Inclusion criteria are age 18 or older, sufficient English proficiency for participation, and a formal BPD diagnosis confirmed by a referring clinician. Exclusion criteria include active psychosis or mania, cognitive impairment, inadequate English comprehension, or participation in another form of psychotherapy during the study period.
Intervention: Internal family systems therapy, developed by Richard Schwartz, is an integrative psychotherapy that conceptualizes the mind as a system of subpersonalities ('parts') organized around a compassionate, stable core Self. The approach promotes internal harmony through increasing awareness, acceptance, and cooperation among these parts and the Self. Participants will receive weekly, one-hour IFS therapy sessions in the private mental health care setting over approximately 12 to 15 months. Treatment will be delivered by two licensed mental health professionals trained in the IFS model. Participants will pay a significantly subsidized session fee to reduce financial burden of participation in the intervention.
Outcomes: The primary outcome is BPD symptom severity measured by the Borderline Symptom List-23 and its supplement. Secondary outcomes include validated measures of emotion dysregulation (DERS-18), shame and guilt (GSQ-8), self-compassion (SCS-SF), interpersonal functioning (EXIS.pers), depression (PHQ-9), anxiety (GAD-7), addictive behaviors (SSBA-G), and well-being (WHO-5). Feasibility and acceptability will be evaluated through attendance, retention, and brief structured questionnaires.
Data collection and analysis: Data will be collected electronically via REDCap, using unique participant IDs and secure storage protocols. Analyses will include paired t-tests for pre-post differences and linear mixed-effects models for repeated measures across all four time points. Effect sizes will be prioritized over probability values when interpreting the results considering relatively low anticipated statistical power.
Timeline: The study begins in early 2026 following ethics approval, with recruitment and intervention delivery extending through the end of 2027. Data analysis, manuscript preparation, and dissemination are planned for 2028.
- Conditions
- Borderline Personality Disorder (BPD)
- Being tested
- Internal family systems therapy
- Keywords
- borderline personality disorder, psychotherapy, effectiveness, internal family systems therapy
- Medical subject headings
- Borderline Personality Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Internal family systems therapyBehavioural
Also called IFS
The internal family systems model was developed by Richard C. Schwartz in the 1980s. This psychotherapy is based on the assumption that the human mind is naturally multiple and consists of interacting sub-personalities ("parts"), including protective and vulnerable parts, shaped by development and adversity. All parts are assumed to have positive intentions, even when their effects are maladaptive; therapy therefore aims to transform rather than eliminate them. Internal family systems therapy further posits the existence of a core Self in every person, characterized by qualities such as compassion, clarity, and calm, which is inherently intact in each individual and capable of leading the internal system. Therapeutic change involves increasing the leadership skills of the core Self, building trusting relationships among parts and the core Self, and unburdening vulnerable parts so they can assume more adaptive roles, supporting improved emotion regulation and well-being.
| Study group | Role | What they receive |
|---|---|---|
| Intervention recipients | Experimental | Participants will engage in internal family systems therapy in the individual format. This form of psychotherapy conceptualizes the mind as a system of subpersonalities ('parts') organized around a compassionate, stable core Self. The approach promotes internal harmony through increasing awareness, acceptance, and cooperation among these parts and the Self. Participants will receive weekly, up to 50, one-hour IFS therapy sessions in the private mental health care setting over approximately 12 to 15 months. Treatment will be delivered by two licensed mental health professionals trained in the IFS model. Participants will pay a significantly subsidized session fee to reduce financial burden of participation in the intervention. Receives: Behavioral: Internal family systems therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Severity of borderline personality disorder symptomatology - disorder-specific mental distress
This first indicator of the primary outcome will be assessed by the Borderline Symptom List (BSL-23, Bohus et al., 2009). This self-report measure consists of items that 1) are based on DSM diagnostic criteria as well as expert opinions and expert-by-experience input; and 2) displayed a high level of sensitivity to change and ability to discriminate individuals with versus without borderline personality disorder. Scale items cover areas such as affective instability, emotional pain, identity disturbance, interpersonal sensitivity, cognitive-perceptual distress, impulsivity-related subjective distress, and suicidal ideation. Total scores range from 0 to 92 with higher scores indicating greater severity of borderline personality disorder symptoms.
Measured: Change in scores between baseline and intervention end (approx. 12-15 months)
Severity of borderline personality disorder symptomatology - dysfunctional behaviors
This second indicator of the primary outcome will be assessed by the supplementary scale of the Borderline Symptom List (BSL). This 11-item scale (BSL-Supplement; Bohus et al., 2007) assesses the extent of dysfunctional behaviours associated with borderline personality disorder such as self-injurious behaviour, suicidality, binge and purge behaviours, impulsivity, hostile outbursts, and sexual promiscuity. Total scores range from 0 to 44 with higher scores reflecting greater frequency or severity of borderline-related behaviors.
Measured: Change in scores between baseline and intervention end (approx. 12-15 months)
Secondary outcomes (8)
Emotion dysregulation
Emotion dysregulation will be assessed using the abbreviated, 18-item version of the Difficulties in Emotion Regulation Scale (DERS-18). The DERS-18 is a self-report measure that captures key dimensions of emotion dysregulation, including lack of emotional clarity, nonacceptance of emotional responses, difficulties engaging in goal-directed behavior, impulse control difficulties, and limited access to effective regulation strategies. Total scores range from 18 to 90, with higher scores indicating greater emotion dysregulation. Despite its brevity, the DERS-18 demonstrates strong psychometric properties and retains coverage of the core domains assessed by the original full-length version (Gratz \& Roemer, 2004).
Measured: Change in scores between baseline and intervention end (approx. 12-15 months)
Addictive behaviors
Addictive behaviours will be assessed using the Generalized Version of the Screener for Substance and Behavioural Addictions (SSBA-G). The SSBA-G is an 8-item, transdiagnostic self-report tool that screens for engagement in and perceived problematic use of a broad range of substances and behaviours (Konkolÿ Thege et al., 2023). Total scores range from 8 to 56, with higher scores indicating more severe addiction-related problems. This tool was selected over disorder- or substance-specific instruments due to its comprehensive scope, brevity, and ability to capture cross-addiction tendencies often observed in the target population.
Measured: Change in scores between baseline and intervention end (approx. 12-15 months)
Interpersonal functioning
Interpersonal functioning will be assessed by the Experience in Personal Social Systems Questionnaire (Hunger et al., 2017). This 12-item scale covers four dimensions in relation to 1) belonging (a sense of being part of a social system); 2) autonomy (ability to demark boundaries based on the belief that the renegotiation of roles, rights, and responsibilities is possible); 3) accord (acceptance of one's social system the way as it is); and 4) confidence (trust in the individual's and their social system's ability to cope with emerging difficulties). Total scores range from 12 to 72, with higher scores indicating better interpersonal functioning. This scale demonstrated good psychometric properties and sensitivity to change in intervention studies. This measure was chosen due to its positive approach to interpersonal functioning (instead of a focus on pathology) and brevity compared to other measures assessing interpersonal functioning.
Measured: Change in scores between baseline and intervention end (approx. 12-15 months)
Shame and guilt
The Guilt and Shame Questionnaire (GSQ-8) is a brief, validated self-report instrument designed to assess the frequency of guilt and shame experiences in the past month (Hoppen et al., 2022). The scale consists of 8 items-four assessing guilt and four assessing shame-rated on a Likert scale. It has demonstrated good internal consistency and a stable two-factor structure across clinical and non-clinical samples. Total scores range from 0 to 32, with higher scores indicating greater levels of guilt and shame. The GSQ-8 is sensitive to changes in self-conscious emotions and provides a concise, practical tool for repeated use in clinical research.
Measured: Change in scores between baseline and intervention end (approx. 12-15 months)
Self-compassion
The Self-Compassion Scale - Short Form (SCS-SF) is a 12-item self-report measure that assesses six key components of self-compassion: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification (Raes et al., 2011). The recommended indicator for this scale is the mean of all items, which score ranges from 1 to 5, with higher scores indicating greater self-compassion. The SCS-SF has demonstrated strong psychometric properties, including good internal consistency and high correlation with the original long-form version.
Measured: Change in scores between baseline and intervention end (approx. 12-15 months)
Anxiety
The Generalized Anxiety Disorder-7 (GAD-7) is a 7-item self-report questionnaire that measures the severity of generalized anxiety symptoms over the past two weeks (Spitzer et al., 2006). Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms. The GAD-7 is brief and has been extensively validated in both general and clinical populations. It has demonstrated good internal consistency, construct validity, and responsiveness to treatment, making it an appropriate tool for evaluating anxiety outcomes in BPD intervention studies.
Measured: Change in scores between baseline and intervention end (approx. 12-15 months)
Depression
The Patient Health Questionnaire-9 (PHQ-9) is a widely used, brief self-report measure that assesses the severity of depressive symptoms over the past two weeks (Kroenke, Spitzer, \& Williams, 2001). It consists of nine items corresponding to DSM-5 diagnostic criteria for major depressive disorder. Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. The PHQ-9 is well-validated across clinical populations, including those with comorbid personality disorders, and demonstrates strong reliability, sensitivity to change, and diagnostic utility.
Measured: Change in scores between baseline and intervention end (approx. 12-15 months)
General psychological well-being
The WHO-5 Well-Being Index is a widely used, validated self-report measure that assesses current mental well-being (World Health Organization, 2024). It consists of five positively worded items related to mood, vitality, and general interest in life. Raw scores range from 0 to 25 (0-100 when transformed as recommended by the developer), with higher scores indicating greater subjective well-being. The WHO-5 is brief, easy to administer, and sensitive to change, making it suitable for both clinical and research settings.
Measured: Change in scores between baseline and intervention end (approx. 12-15 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2026
- Study startFeb 2026 (estimated)
- Primary completionDec 2027 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Borderline Personality Disorder (BPD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Waypoint Centre for Mental Health Care
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Barna Konkoly-Thege, Waypoint Centre for Mental Health Care
- Investigators
- Barna Konkoly-Thege, PhD, Principal investigator, Waypoint Centre for Mental Health Care
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07342907
- Sponsor's protocol ID
- IFS for BPD
- Acronym
- IFS for BPD
- Status last verified
- Jan 2026
- First submitted
- 6 Jan 2026
- Last updated
- 16 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: A public repository dataset will be created from the anonymized data of those participants only who provided explicit consent during the informed consent process to allow their data to be stored in a data repository for secondary analyses. This dataset will be uploaded to a controlled-access repository (University of Toronto Dataverse within the Borealis network).
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Internal Family Systems Therapy in Improving Mental Health in Individuals With Borderline Personality Disorder
- ClinicalTrials.gov ID
- NCT07342907
- Acronym / sponsor ID
- IFS for BPD / IFS for BPD
- Conditions
- Borderline Personality Disorder (BPD)
- Keywords
- borderline personality disorder, psychotherapy, effectiveness, internal family systems therapy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Waypoint Centre for Mental Health CareUniversity, hospital or other
- Study start
- Feb 2026 (estimated)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 15 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Borderline Personality Disorder (BPD) involves intense emotional ups and downs, unstable relationships, impulsivity, and a poor sense of self. These challenges often lead to addiction, self-harm, and frequent use of healthcare services. While certain treatments already in practice - such as dialectical behavior therapy - can help, they don't work for everyone or address all aspects of the disorder. This study plans to explore internal family systems (IFS) therapy, a method that views the mind as made up of different "parts" - each with its own thoughts and feelings. IFS helps people build understanding and compassion toward these parts and connect with a calmer, more centered "Self." This may be especially useful for those with BPD, who often feel fragmented and extremely critical of themselves and others. This will be the first study to examine internal family systems therapy for BPD. The participants (15 in total) will receive up to 50 individual sessions over 15 months. Changes in symptoms and overall mental health will be measured at four points during the study. People with lived experience of BPD will help shape the research to ensure it is relevant, respectful, and useful for others facing similar challenges.
Detailed description
Brief background and rationale: Borderline personality disorder (BPD) is a chronic and disabling psychiatric condition marked by pervasive affective instability, identity disturbance, interpersonal dysfunction, and impulsivity. It affects approximately 1-2% of the general population and up to 20% of psychiatric populations, contributing substantially to healthcare utilization, suicide risk, and long-term disability. Existing evidence-based psychotherapies for this condition, such as dialectical behavior therapy, mentalization-based therapy, or schema therapy show significant benefits but these are modest and these interventions are quite resource-intensive. There remains a need for additional, theoretically grounded treatments that target core pathomechanisms of BPD-particularly emotion dysregulation, shame, and self-fragmentation.
Objectives: The primary objective of this pilot study is to assess preliminary effectiveness of internal family systems (IFS) therapy in reducing BPD symptom severity from baseline to post-treatment. Secondary objectives are to evaluate changes in emotion dysregulation, shame, self-compassion, interpersonal functioning, depression, anxiety, addictive behaviors and overall well-being; as well as to assess feasibility (recruitment, retention, adherence), acceptability, and safety. It is hypothesized that participants will demonstrate at least small-to-moderate improvements in BPD symptom severity, with congruent changes across secondary outcomes. Although clinical interest in IFS has grown exponentially in the past decades, empirical evaluation remains limited, and no studies to date have specifically examined its use in any personality disorder. Given the strong theoretical fit between IFS principles and BPD phenomenology, a structured pilot investigation is warranted to establish feasibility, safety, and preliminary effectiveness prior to larger controlled trials.
Study design: The study will use a single-group, repeated-measures design with assessments at baseline, 4 months, 8 months, and post-intervention (12-15 months). A target sample of fifteen adults will be recruited. Inclusion criteria are age 18 or older, sufficient English proficiency for participation, and a formal BPD diagnosis confirmed by a referring clinician. Exclusion criteria include active psychosis or mania, cognitive impairment, inadequate English comprehension, or participation in another form of psychotherapy during the study period.
Intervention: Internal family systems therapy, developed by Richard Schwartz, is an integrative psychotherapy that conceptualizes the mind as a system of subpersonalities ('parts') organized around a compassionate, stable core Self. The approach promotes internal harmony through increasing awareness, acceptance, and cooperation among these parts and the Self. Participants will receive weekly, one-hour IFS therapy sessions in the private mental health care setting over approximately 12 to 15 months. Treatment will be delivered by two licensed mental health professionals trained in the IFS model. Participants will pay a significantly subsidized session fee to reduce financial burden of participation in the intervention.
Outcomes: The primary outcome is BPD symptom severity measured by the Borderline Symptom List-23 and its supplement. Secondary outcomes include validated measures of emotion dysregulation (DERS-18), shame and guilt (GSQ-8), self-compassion (SCS-SF), interpersonal functioning (EXIS.pers), depression (PHQ-9), anxiety (GAD-7), addictive behaviors (SSBA-G), and well-being (WHO-5). Feasibility and acceptability will be evaluated through attendance, retention, and brief structured questionnaires.
Data collection and analysis: Data will be collected electronically via REDCap, using unique participant IDs and secure storage protocols. Analyses will include paired t-tests for pre-post differences and linear mixed-effects models for repeated measures across all four time points. Effect sizes will be prioritized over probability values when interpreting the results considering relatively low anticipated statistical power.
Timeline: The study begins in early 2026 following ethics approval, with recruitment and intervention delivery extending through the end of 2027. Data analysis, manuscript preparation, and dissemination are planned for 2028.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intervention recipients | Experimental | Behavioral: Internal family systems therapyParticipants will engage in internal family systems therapy in the individual format. This form of psychotherapy conceptualizes the mind as a system of subpersonalities ('parts') organized around a compassionate, stable core Self. The approach promotes internal harmony through increasing awareness, acceptance, and cooperation among these parts and the Self. Participants will receive weekly, up to 50, one-hour IFS therapy sessions in the private mental health care setting over approximately 12 to 15 months. Treatment will be delivered by two licensed mental health professionals trained in the IFS model. Participants will pay a significantly subsidized session fee to reduce financial burden of participation in the intervention. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Resident of Ontario, Canada;
- Sufficient fluency in English to provide informed consent, participate in therapy sessions, and complete self-reported assessments;
- Diagnosis of borderline personality disorder confirmed by a healthcare professional authorized to establish such a diagnosis in Ontario;
- Willingness and ability (including financial means) to participate in the 50-session, 12-15-month intervention and the study assessments;
- Capacity and willingness to provide written informed consent.
Key exclusion criteria (4 listed)
- Current manic or psychotic symptoms regardless of diagnosis;
- Substance dependence severe enough to interfere with meaningful level of engagement in the study intervention.
- Cognitive impairment or neurological disorders that would preclude informed consent or meaningful participation in the study intervention.
- Concurrent participation in any another form of psychotherapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Internal family systems therapyAlso: IFSThe internal family systems model was developed by Richard C. Schwartz in the 1980s. This psychotherapy is based on the assumption that the human mind is naturally multiple and consists of interacting sub-personalities ("parts"), including protective and vulnerable parts, shaped by development and adversity. All parts are assumed to have positive intentions, even when their effects are maladaptive; therapy therefore aims to transform rather than eliminate them. Internal family systems therapy further posits the existence of a core Self in every person, characterized by qualities such as compassion, clarity, and calm, which is inherently intact in each individual and capable of leading the internal system. Therapeutic change involves increasing the leadership skills of the core Self, building trusting relationships among parts and the core Self, and unburdening vulnerable parts so they can assume more adaptive roles, supporting improved emotion regulation and well-being. | Behavioural | Intervention recipients |
Primary outcome
Severity of borderline personality disorder symptomatology - disorder-specific mental distress
Time frame: Change in scores between baseline and intervention end (approx. 12-15 months)
This first indicator of the primary outcome will be assessed by the Borderline Symptom List (BSL-23, Bohus et al., 2009). This self-report measure consists of items that 1) are based on DSM diagnostic criteria as well as expert opinions and expert-by-experience input; and 2) displayed a high level of sensitivity to change and ability to discriminate individuals with versus without borderline personality disorder. Scale items cover areas such as affective instability, emotional pain, identity disturbance, interpersonal sensitivity, cognitive-perceptual distress, impulsivity-related subjective distress, and suicidal ideation. Total scores range from 0 to 92 with higher scores indicating greater severity of borderline personality disorder symptoms.
Severity of borderline personality disorder symptomatology - dysfunctional behaviors
Time frame: Change in scores between baseline and intervention end (approx. 12-15 months)
This second indicator of the primary outcome will be assessed by the supplementary scale of the Borderline Symptom List (BSL). This 11-item scale (BSL-Supplement; Bohus et al., 2007) assesses the extent of dysfunctional behaviours associated with borderline personality disorder such as self-injurious behaviour, suicidality, binge and purge behaviours, impulsivity, hostile outbursts, and sexual promiscuity. Total scores range from 0 to 44 with higher scores reflecting greater frequency or severity of borderline-related behaviors.
8 secondary outcomes
Emotion dysregulation
Time frame: Change in scores between baseline and intervention end (approx. 12-15 months)
Addictive behaviors
Time frame: Change in scores between baseline and intervention end (approx. 12-15 months)
Interpersonal functioning
Time frame: Change in scores between baseline and intervention end (approx. 12-15 months)
Shame and guilt
Time frame: Change in scores between baseline and intervention end (approx. 12-15 months)
Self-compassion
Time frame: Change in scores between baseline and intervention end (approx. 12-15 months)
Anxiety
Time frame: Change in scores between baseline and intervention end (approx. 12-15 months)
Depression
Time frame: Change in scores between baseline and intervention end (approx. 12-15 months)
General psychological well-being
Time frame: Change in scores between baseline and intervention end (approx. 12-15 months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2026.
- Individual participant dataSharing planned: Yes. A public repository dataset will be created from the anonymized data of those participants only who provided explicit consent during the informed consent process to allow their data to be stored in a data repository for secondary analyses. This dataset will be uploaded to a controlled-access repository (University of Toronto Dataverse within the Borealis network).
Related trials for Borderline Personality Disorder (BPD)
Recruiting
Repetitive Transcranial Magnetic Stimulation Versus Theta Burst Stimulation on Impulsivity, Emotional Dysregulation, and Non-Suicidal Self-Injury in Borderline Personality Disorder Patients
Borderline Personality Disorder (BPD)
Not yet recruitingPhase 2
Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder
Infusion of Ketamine in Severe Borderline Personality Disorder, Borderline Personality Disorder (BPD)
Recruiting
Combining Transcranial Magnetic Stimulation With Emotion Regulation Skills Training in Borderline Personality Disorder
Borderline Personality Disorder (BPD)
Recruiting
Effectiveness of Enhanced Dialectical Behavior Therapy Skills Training Group for Borderline Personality Disorder
Borderline Personality Disorder (BPD), Dialectical Behavior Therapy
RecruitingObservational study
Long Term Follow-up of Mentalization-Based Treatment: Exploring Variability in Outcomes, Long-term Value and Experiences 10+ Year After Receiving MBT Day Hospital or MBT Intensive Outpatient
Borderline Personality Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Barna Konkoly-Thege, PhD principal investigator
Waypoint Centre for Mental Health Care
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Internal family systems therapy in people with Borderline Personality Disorder (BPD), run by Waypoint Centre for Mental Health Care at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Barna Konkoly-Thege, PhD (705-549-3181 ext. 2614, bkonkoly-thege@waypointcentre.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Severity of borderline personality disorder symptomatology - disorder-specific mental distress (time frame: Change in scores between baseline and intervention end (approx. 12-15 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2026.